attana - sensor technologies

Attana and Partners Awarded €1.1 Million Grant

Attana and partners receive a project grant of €1.1 million from KK-Stiftelsen for the development of methods for characterization and quality control of biopharmaceutical purification.

Stockholm June 27th, 2017 – Attana AB, AstraZeneca, Akzo Nobel Pulp and Performance Chemicals AB and Ridgeview Instruments AB together with Karlstad University, Linnaeus University and Örebro University has been granted €1.1 million from The Swedish Knowledge Foundation (KK-stiftelsen).

The project aims at developing flexible processes for quality control of biopharmaceutical production. The ambition is to allow continuous improvements of the analytical methods used for quality control without the need for costly and time consuming regulatory approval every time an improvement is implemented.

"Currently pharmaceutical companies need to follow the regulatory approved method in detail. The consequence of that, is that when improvements are made they are forced to use the old approved methods or submit expensive and time-consuming requests for changes to the regulatory authorities," says Prof. Torgny Fornstedt at Karlstad University.

"Every time we have changed a regulatory approved analytical method for quality control, we have had to pay several hundred thousand of euros in fees to regulatory authorities around the world and it can take up to two years to obtain the approval," says Dr. Anders Karlsson, Head of Quality Control at AstraZeneca R&D Gothenburg.

"This project is state of the art both scientifically and in volume. It is a strategically important project for the collaboration between industry and universities in Sweden and will include a significant amount of knowledge transfer between the contributing partners," says Mats Waltré, Program Manager at KK-stiftelsen.

"Attana´s 3rd generation biosensor is a perfect match for this kind of characterization, where our detailed interaction profiling can detect the influence of small amounts of contamination on the interaction performances," concludes Dr. Teodor Aastrup, CEO and co-founder of Attana.

About Attana:

Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera and cell-based assays. Attana’s products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. Attana Movie